These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 14584452

  • 1. [Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
    MMW Fortschr Med; 2003 Sep 11; 145(37):65. PubMed ID: 14584452
    [No Abstract] [Full Text] [Related]

  • 2. [Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
    MMW Fortschr Med; 2003 Oct 09; 145(41):47. PubMed ID: 14655486
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Timely intervention with insulin sensitizer. Controlling cardiovascular risks].
    MMW Fortschr Med; 2003 Jun 05; 145(23):56-7. PubMed ID: 12854228
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
    Lehmann DF, Lohray BB.
    J Clin Pharmacol; 2008 Aug 05; 48(8):999-1002. PubMed ID: 18650500
    [No Abstract] [Full Text] [Related]

  • 9. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
    Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G.
    J Intern Med; 2007 Mar 05; 261(3):293-305. PubMed ID: 17305652
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G.
    J Diabetes Complications; 2005 Mar 05; 19(3):168-77. PubMed ID: 15866064
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr 05; 46(4):25-9. PubMed ID: 18403615
    [Abstract] [Full Text] [Related]

  • 20. How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
    Freemantle N.
    BMJ; 2005 Oct 08; 331(7520):836-8. PubMed ID: 16210286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.